Nucleic Acids Research,
Journal Year:
2024,
Volume and Issue:
53(D1), P. D1302 - D1312
Published: Dec. 16, 2024
Gene
fusions
are
nucleotide
sequences
formed
due
to
errors
in
replication
and
transcription
control.
These
errors,
resulting
from
chromosomal
translocation,
transcriptional
or
trans-splicing,
vary
cell
cell.
The
identification
of
has
become
critical
as
key
biomarkers
for
disease
diagnosis
therapy
various
cancers,
significantly
influencing
modern
medicine.
Chimeric
Transcripts
RNA-Sequencing
database
version
8.0
(ChiTaRS
8.0;
http://biosrv.org/chitars)
is
a
specialized
repository
human
chimeric
transcripts,
containing
47
445
curated
RNA
transcripts
over
100
000
humans.
This
updated
provides
unique
information
on
1055
breakpoints
derived
public
datasets
using
chromosome
conformation
capture
techniques
(the
Hi-C
datasets).
It
also
includes
an
expanded
list
gene
that
potential
drug
targets,
across
934
lines,
positioning
ChiTaRS
valuable
resource
testing
personalized
cancer
therapies.
By
utilizing
text
mining
selection
disease-specific
RNA-sequencing
data
datasets,
well
patient
blood
plasma
samples,
we
have
identified
novel
chimeras-particularly
diseases
such
oral
squamous
carcinoma
glioblastoma-now
catalogued
ChiTaRS.
Thus,
serves
enhanced
fusion
transcript
incorporates
insights
into
the
functional
landscape
chimeras
cancers
other
complex
diseases,
based
liquid
biopsy
results.
Cancer Science,
Journal Year:
2024,
Volume and Issue:
115(4), P. 1060 - 1072
Published: Feb. 3, 2024
Abstract
Liquid
biopsy
is
emerging
as
a
pivotal
tool
in
precision
oncology,
offering
noninvasive
and
comprehensive
approach
to
cancer
diagnostics
management.
By
harnessing
biofluids
such
blood,
urine,
saliva,
cerebrospinal
fluid,
pleural
effusions,
this
technique
profiles
key
biomarkers
including
circulating
tumor
DNA,
cells,
microRNAs,
extracellular
vesicles.
This
review
discusses
the
extended
scope
of
liquid
biopsy,
highlighting
its
indispensable
role
enhancing
patient
outcomes
through
early
detection,
continuous
monitoring,
tailored
therapy.
While
advantages
are
notable,
we
also
address
challenges,
emphasizing
necessity
for
precision,
cost‐effectiveness,
standardized
methodologies
broader
application.
The
future
trajectory
set
expand
reach
personalized
medicine,
fueled
by
technological
advancements
collaborative
research.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(16), P. 8594 - 8594
Published: Aug. 6, 2024
Liquid
biopsy,
a
noninvasive
diagnosis
that
examines
circulating
tumor
components
in
body
fluids,
is
increasingly
used
cancer
management.
An
overview
of
relevant
literature
emphasizes
the
current
state
liquid
biopsy
applications
care.
Biomarkers
particularly
DNA
(ctDNA),
RNAs
(ctRNA),
cells
(CTCs),
extracellular
vesicles
(EVs),
and
other
components,
offer
promising
opportunities
for
early
diagnosis,
treatment
selection,
monitoring,
disease
assessment.
The
implementation
precision
medicine
has
shown
significant
potential
various
types,
including
lung
cancer,
colorectal
breast
prostate
cancer.
Advances
genomic
molecular
technologies
such
as
next-generation
sequencing
(NGS)
digital
polymerase
chain
reaction
(dPCR)
have
expanded
utility
enabling
detection
somatic
variants
actionable
alterations
tumors.
also
demonstrated
predicting
responses,
monitoring
minimal
residual
(MRD),
assessing
heterogeneity.
Nevertheless,
standardizing
techniques,
interpreting
results,
integrating
them
into
clinical
routine
remain
challenges.
Despite
these
challenges,
implications
management,
offering
dynamic
approach
to
understanding
biology
guiding
personalized
strategies.
Cancer Letters,
Journal Year:
2024,
Volume and Issue:
unknown, P. 217350 - 217350
Published: Nov. 1, 2024
Pancreatic
cancer
remains
one
of
the
most
challenging
malignancies
to
treat
due
its
late-stage
diagnosis,
aggressive
progression,
and
high
resistance
existing
therapies.
This
review
examines
latest
advancements
in
early
detection,
therapeutic
strategies,
with
a
focus
on
emerging
biomarkers,
tumor
microenvironment
(TME)
modulation,
integration
artificial
intelligence
(AI)
data
analysis.
We
highlight
promising
including
microRNAs
(miRNAs)
circulating
DNA
(ctDNA),
that
offer
enhanced
sensitivity
specificity
for
early-stage
diagnosis
when
combined
multi-omics
panels.
A
detailed
analysis
TME
reveals
how
components
such
as
cancer-associated
fibroblasts
(CAFs),
immune
cells,
extracellular
matrix
(ECM)
contribute
therapy
by
creating
immunosuppressive
barriers.
also
discuss
interventions
target
these
components,
aiming
improve
drug
delivery
overcome
evasion.
Furthermore,
AI-driven
analyses
are
explored
their
potential
interpret
complex
data,
enabling
personalized
treatment
strategies
real-time
monitoring
response.
conclude
identifying
key
areas
future
research,
clinical
validation
regulatory
frameworks
AI
applications,
equitable
access
innovative
comprehensive
approach
underscores
need
integrated,
outcomes
pancreatic
cancer.
Neuro-Oncology Advances,
Journal Year:
2024,
Volume and Issue:
6(1)
Published: Jan. 1, 2024
Abstract
Brain
metastases
remain
a
challenging
and
feared
complication
for
patients
with
cancer
research
in
this
area
has
lagged
behind
into
to
other
organs.
Due
their
location
the
risks
associated
neurosurgical
biopsies,
biology
underpinning
brain
response
treatment
evolution
over
time
remains
poorly
understood.
Liquid
biopsies
are
proposed
overcome
many
of
limitations
present
tissue
providing
better
representation
tumor
heterogeneity,
facilitating
repeated
sampling,
noninvasive
assessment
biology.
Several
different
liquid
biopsy
approaches
have
been
investigated
including
circulating
cells,
DNA,
extracellular
vesicles,
tumor-educated
platelets;
however,
these
generally
less
effective
assessing
compared
organs
requiring
improved
techniques
investigate
approaches,
studies
combining
and/or
novel
approaches.
Through
review,
we
highlight
current
state
art
define
key
unanswered
questions
related
biopsies.
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(3), P. 917 - 917
Published: Jan. 22, 2025
Advances
in
neuro-oncology
have
transformed
the
diagnosis
and
management
of
brain
tumors,
which
are
among
most
challenging
malignancies
due
to
their
high
mortality
rates
complex
neurological
effects.
Despite
advancements
surgery
chemoradiotherapy,
prognosis
for
glioblastoma
multiforme
(GBM)
metastases
remains
poor,
underscoring
need
innovative
diagnostic
strategies.
This
review
highlights
recent
imaging
techniques,
liquid
biopsies,
artificial
intelligence
(AI)
applications
addressing
current
challenges.
Advanced
including
diffusion
tensor
(DTI)
magnetic
resonance
spectroscopy
(MRS),
improve
differentiation
tumor
progression
from
treatment-related
changes.
Additionally,
novel
positron
emission
tomography
(PET)
radiotracers,
such
as
18F-fluoropivalate,
18F-fluoroethyltyrosine,
18F-fluluciclovine,
facilitate
metabolic
profiling
high-grade
gliomas.
Liquid
biopsy,
a
minimally
invasive
technique,
enables
real-time
monitoring
biomarkers
circulating
DNA
(ctDNA),
extracellular
vesicles
(EVs),
cells
(CTCs),
tumor-educated
platelets
(TEPs),
enhancing
precision.
AI-driven
algorithms,
convolutional
neural
networks,
integrate
tools
accuracy,
reduce
interobserver
variability,
accelerate
clinical
decision-making.
These
innovations
advance
personalized
neuro-oncological
care,
offering
new
opportunities
outcomes
patients
with
central
nervous
system
tumors.
We
advocate
future
research
integrating
these
into
workflows,
accessibility
challenges,
standardizing
methodologies
ensure
broad
applicability
neuro-oncology.
Current Issues in Molecular Biology,
Journal Year:
2025,
Volume and Issue:
47(4), P. 235 - 235
Published: March 28, 2025
Cancer
is
a
significant
global
health
challenge,
where
early
diagnosis
crucial
for
enhancing
patient
survival
and
mitigating
the
treatment
burden
on
patients.
Exosomes
are
extracellular
vesicles
released
through
fusion
of
multivesicular
bodies
with
cell
membranes,
carrying
disease-associated
information
from
donor
cells.
This
makes
exosomes
key
biomarker
in
liquid
biopsy
analysis,
particularly
cancer
detection.
Developing
cost-effective,
straightforward,
sensitive
exosome
biosensing
technologies
practical
importance.
To
date,
large
number
fluorescence-based
biosensors
have
relied
Fluorescence
Resonance
Energy
Transfer
(FRET)
principle.
review
introduces
basic
background
field
principle
FRET-based
sensors,
followed
by
systematic
summary
their
progress
categorized
different
transduction
elements
or
mechanisms.
Finally,
this
work
discusses
current
challenges
proposes
potential
solutions
future
prospects,
aiming
to
encourage
inspire
development
new
approaches
advanced
FRET
biosensors.
